Poor delivery characteristics of potential drug candidates are efficiently overcome by the exploitation of bio reversible chemical derivatization or in other words the prodrug approach. Prodrugs are inert or less dynamic subsidiaries of Drug Molecules that experience substance or enzymatic change in vivo to discharge the dynamic Drug moiety answerable for inspiring pharmacological impacts. Prodrug design comprises an area of drug research devoted to the optimization of drug delivery where the pharmacologically inactive prodrug requires transformation within the body in order to release the active drug. This approach has many advantages. First, the changes in physicochemical properties and the pharmacological profile of the drug are transient since the well-characterized parent drug molecule is regenerated from the prodrug. Second, the introduction of several chemical transient changes in the drug molecule is possible allowing prodrug derivatives with a broad spectrum of physicochemical properties to be synthesized. Prodrug undergoes quantitative chemical or enzymatic conversion to the parent compound (and a nontoxic transport-moiety). Prodrug formation can thus be considered as a means to mask temporarily undesirable physicochemical properties of the parent molecule.
Sub-Tracks
· Enzymatic hydrolysis of Prodrugs
· Nalmefene prodrugs
· Strategies for Paclitaxel.
· Troxacitabine prodrugs
· Amino acids as promote ties in prodrug
· Prodrugs for Gene-Directed Enzyme-Prodrug treatment
· Lipid prodrug nanocarriers in cancer treatment
· Analgesic Prodrugs for Combating their Side-Effects
· Effect of Simvastatin Prodrug macromolecular prodrug
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
